Uncategorized
Lilly’s Foundayo posts ‘outstanding’ diabetes data, possibly easing FDA safety concerns
Right after the FDA flagged safety concerns for Eli Lilly’s newly approved obesity pill, the pharma posted diabetes data demonstrating a clean safety profile and revealed plans to seek approval in the indication.